Let's Talk About CKD
Chronic kidney disease (CKD) is a common1 yet widely underrecognized and potentially deadly condition2,3 and is estimated to affect more than 160 million people with type 2 diabetes (T2D) worldwide.4,5,6 CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced.7,8
In addition, patients with CKD and T2D are approximately three times more likely to die from a cardiovascular (CV)-related cause than those with T2D alone.9
Hear from leading experts below on how outcomes can be improved for patients living with CKD and T2D, alongside insights from their experience and best practices.
Diabetologist
Professor Peter Rossing
Head of Complications Research at Steno Diabetes Center Copenhagen, Denmark
Cardiologist
Professor Carolyn Lam
Senior Consultant of the National Heart Centre, Singapore
Primary Care Physician
Professor Richard Hobbs
Nuffield Professor of Primary Care Health Sciences, UK
Nephrologist
Professor Christoph Wanner
Professor of Medicine and Head of the Division of Nephrology University Hospital of Würzburg, Germany
INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH CKD AND T2D
The risk of CV events such as myocardial infarction or hospitalisation for heart failure appears early in the course of CKD in T2D, and grows with disease severity10 – leading to an increased risk of experiencing a fatal CV event. Learn why cardiovascular management should be considered for patients with CKD and T2D as early as possible.
The Silent Nature of CKD in T2D
A panel discussion on chronic kidney disease in T2D with four key opinion leaders.
The Need for a Collaborative Multidisciplinary Approach in CKD in T2D
The panel discusses what comprises a collaborative approach for patients with CKD in T2D that need multidisciplinary care.
Early Detection & Intervention in CKD and T2D
The panel discusses the type of tests and the testing protocols that are involved in diagnosing CKD early.
Patient Education in CKD in T2D
The panel discusses the key challenges when clinicians discuss kidney health with patients with CKD and T2D.
The Role of Healthcare Providers Beyond the Specialists
The panel discusses the different roles of health care providers to support the management of patients with CKD and T2D as a broader team.
References:
- NHS.UK. Chronic kidney disease. Available at: https://www.nhs.uk/conditions/kidney-disease/. 2019. [Last Accessed: April 2022]. Return to content
- Breyer MD et al. Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in Nephrology. 2016. 36(6), 436–447. Return to content
- National Kidney Foundation. 2021. Chronic Kidney Disease Goes Undetected in Those Most at Risk. Available at: https://www.kidney.org/news/newsroom/nr/CKD-Goes-Undetected-in-Those-Most-at-Risk. Last Accessed: April 2022. Return to content
- Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018. 14(2), 88-98. Return to content
- Wu B, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Research and Care. 2016. 4(1), e000154. Return to content
- International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium; 2019. Return to content
- Khan et al. Prevalence of Chronic Kidney Disease in Asia: A Systematic Review of Population-Based StudiesJ Coll Physicians Surg Pak. 2018. 28(12):960-966. Return to content
- Zhong J, et al. A perspective on chronic kidney disease progression. American Journal of Physiology-Renal Physiology. 2017. 312(3), F375-F384. Return to content
- Afkarian M, et al. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. Journal of the American Society of Nephrology. 2013. 24(2), 302-8. Return to content
- Amod A, et al. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11) Diabetes Ther. 2020. 11(1):53-70. Return to content
Follow:
© 2022 Bayer AG
Last updated in June 2022
This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.
- PP-KER-ALL-0067-1
